Skip to main content

Registration is open for the following webinar:

Webinar: Bringing Mesenchymal Stem Cells into the Clinic (EMEA Time)

Bringing Mesenchymal Stem Cells into the Clinic (EMEA)
13 June
12:00 BST / 13:00 CEST

Mesenchymal stem cells (MSCs) are multipotent adult stem cells that have been defined and studied for several decades for their clinical potential. Indeed, these cells continue to be the source of numerous clinical trials, and interest in their use for therapeutic purposes continues to grow. Allogeneic MSCs are particularly interesting for their favorable safety profile, thanks to their low immunogenic potential and their multiple beneficial properties. Indeed, they have the ability to self-renew and differentiate into multiple cell lineages, including bone, chondrocytes, adipocytes, and cardiomyocytes, making them an attractive source for cell-based regenerative therapies. MSCs also have an immunomodulatory and anti-inflammatory effect on innate and adaptive immune cells. As inflammation is considered the primary cause of many diseases, the anti-inflammatory property plays an essential role in the therapeutic use of MSCs. Moreover, these cells can be isolated from almost any vascularized tissue, including bone marrow, adipose tissue, and umbilical cord.

Despite the promising results accumulated over the years and in clinical trials, few companies worldwide have been able to produce and market MSCs as a cell therapy. CellColabs is positioned as one of the world leaders in the large-scale production of affordable allogeneic MSCs. Throughout the production process, our cellular product undergoes rigorous quality control, including tests to ensure the sterility, purity, viability, and activity of the cells.

Our MSCs has thus obtained the authorization for clinical use of the cells in the Bahamas and the Maldives, where patients have benefited from our cell therapy for the treatment of pathologies such as knee arthritis, sports injuries, preventive and aging frailty, and cardiovascular disease.

Moving forward, our focus remains on expanding and diversifying our sources of MSCs to meet the escalating demand for Good Manufacturing Practice (GMP)-compliant stem cells within the healthcare sector. Through continued innovation and dedication to excellence, we are poised to address the evolving needs of patients and healthcare professionals worldwide.

About the Speaker

KatiaLefsihanePictKatia Lefsihane had the privilege of collaborating closely with Professor Katarina Le Blanc as a research assistant in the field of regenerative medicine at the prestigious Karolinska Institute in Sweden. Following this enriching experience, she returned to France to pursue a PhD at the INSERM Institute in Lyon, where she specialized in transplant immunology within a research group focused on developing innovative therapeutic strategies to mitigate transplant rejection. After successfully defending my thesis in December 2023, she was honored to join CellColabs, a pioneering startup dedicated to the large-scale manufacturing of advanced cell therapies with the goal of broadening accessibility to them. In her role, she splits time between contributing to the research and development endeavors of the company and serving as a product specialist for the business development team.

Register for this webinar